Trial Profile
A Phase II, Multinational Clinical Study of NOX66 (Veyonda) in a Broad Spectrum of Solid Cancers Including Rare Cancers
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary)
- Indications Lung cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms DARRT-2
- Sponsors Noxopharm
- 24 Apr 2023 According to a Noxopharm media release, the process to discontinue trial has commenced, with trial sites notified and final dosing dates for patients being determined. A safety follow-up period will occur after the last treatment as per regulatory requirements, and the company will continue to offer existing trial patients and their doctors the opportunity to access Veyonda via a tailored compassionate use program, pending FDA approval.
- 24 Apr 2023 According to a Noxopharm media release, the company discontinued trial due to slow patient recruitment due to the ongoing COVID impact on the US healthcare system, as well as challenges with patients accepting the drug's suppository delivery method, led to a projected unsustainable rise in costs and trial delays.
- 24 Apr 2023 Status changed from recruiting to discontinued, according to a Noxopharm media release.